Second-Line Therapy for Type 2 Diabetes After Metformin
Rationale for Selection
- The American College of Physicians strongly recommends adding either an SGLT-2 inhibitor or a GLP-1 receptor agonist to metformin in patients with inadequate glycemic control (high-certainty evidence) 1
- These agents are preferred over other options due to their demonstrated benefits in reducing all-cause mortality and major adverse cardiovascular events 1
- The American Diabetes Association and European Association for the Study of Diabetes consensus report supports selecting medication added to metformin based on patient characteristics and comorbidities 2
Specific Recommendations Based on Patient Characteristics
- For patients with or at risk for heart failure, SGLT-2 inhibitors should be prioritized 1
- For patients with chronic kidney disease, SGLT-2 inhibitors should be prioritized 1
- For patients desiring weight reduction, SGLT-2 inhibitors can be considered 2, 3
- For patients wanting to avoid hypoglycemia, SGLT-2 inhibitors can be considered 2
- For patients with increased risk for stroke, GLP-1 receptor agonists should be prioritized 1
Clinical Considerations for This Patient
- With an HbA1c of 6.8%, this patient may benefit from additional therapy to maintain glycemic control and gain cardiovascular/renal protection 1, 4
- The American College of Physicians guideline recommends aiming for HbA1c levels between 7% and 8% in most adults with type 2 diabetes 4
- Consider lower doses of the added medication to avoid hypoglycemia 1
- Focus on agents with cardiovascular and renal benefits rather than just further HbA1c reduction 1, 5
Advantages of SGLT-2 Inhibitors and GLP-1 Receptor Agonists
- SGLT-2 inhibitors reduce risk for all-cause mortality, major adverse cardiovascular events, progression of chronic kidney disease, and hospitalization for heart failure 1, 5
- GLP-1 receptor agonists reduce risk for all-cause mortality, major adverse cardiovascular events, and stroke 1
- Both classes promote weight loss rather than weight gain 2
- Both have low risk of hypoglycemia when combined with metformin 2, 3
Medications to Avoid as Second-Line Agents
- DPP-4 inhibitors are not recommended for reducing morbidity and mortality (strong recommendation, high-certainty evidence) 1
- Sulfonylureas are associated with weight gain and higher risk of hypoglycemia 2, 6
- Thiazolidinediones are associated with weight gain, fluid retention, increased risk of heart failure, and possible increased risk of bladder cancer 6, 7
- Insulin is generally reserved for patients with more severe hyperglycemia or symptoms of hyperglycemia 8, 9
Implementation Considerations
- Start with low doses and titrate as needed 5
- Monitor renal function when using SGLT-2 inhibitors (dose adjustments required with eGFR <60 mL/min/1.73m²) 5, 10
- Consider cost and insurance coverage, as these newer agents are typically more expensive than older options 2, 9